SAN DIEGO, Oct. 26, 2017 /PRNewswire/ -- ResMed Inc.
(NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2017. Revenue for the quarter was
$523.7 million, a 13 percent increase compared to the same period of the prior year.
"We started the fiscal year with strong 11 percent constant currency revenue growth led by our masks, software-as-a-service
solutions, and devices," said Mick Farrell, ResMed's chief executive officer. "Our new masks
have performed well around the world, device sales are solid, and operating profit returned to double-digit growth in the
quarter."
Farrell concluded, "We are achieving share gains with new product innovation and delivering sustainable operating profit
growth. We continue to pioneer products, services and solutions that improve patient outcomes, create efficiencies for our
homecare providers, and help physicians and payers better manage chronic disease and lower long-term healthcare costs."
Analysis of first quarter results
First quarter revenue in the Americas, excluding Brightree, was $296.6 million, an 11 percent
increase over the same period of the prior year. Brightree revenue for the first quarter was $38.1
million, an increase of 15 percent compared to the same period of the prior year. Revenue in combined EMEA and APAC was
$189.0 million, an increase of 11 percent on a constant currency basis, compared to the same period
of the prior year.
Gross margin in the first quarter was 58.4 percent, higher than the prior year's quarter gross margin of 57.8 percent. The
improvement in gross margin compared to prior year was due to manufacturing and procurement efficiencies and the prior year
Astral field safety notification expenses, which were partially offset by declines in average selling prices.
Income from operations for the quarter was $112.6 million, a 20 percent increase compared with
the quarter ended September 30, 2016. Non-GAAP income from operations for the quarter was $124.3
million, a 12 percent increase compared to the same period of the prior year.
Selling, general and administrative expenses were $143.9 million, a 12 percent increase over the
same period in the prior year, or a 10 percent increase on a constant currency basis. SG&A expenses improved to 27.5 percent
of revenue in the quarter, compared with 27.7 percent reported in the quarter ended September 30, 2016.
Research and development expenses were $37.4 million, or 7.1 percent of revenue. R&D
expenses increased by 9 percent compared with the same period last year, or a 6 percent increase on a constant currency
basis.
Amortization of acquired intangible assets was $11.8 million during the quarter, which is
consistent with the same period last year. Stock-based compensation costs incurred during the quarter of $11.9 million consisted of expenses associated with employee equity grants, and our employee stock purchase
plan.
Net income for the quarter was $86.1 million, a 13 percent increase compared to the same period
of the prior year. Non-GAAP net income was $94.1 million, a 7 percent increase compared to the
prior year.
Non-GAAP measures adjust for amortization of acquired intangibles and the Astral battery field safety notification
expenses.
GAAP diluted earnings per share for the quarter increased by 11 percent to $0.60. Non-GAAP
diluted earnings per share of $0.66 were 6 percent higher compared with the same period of the
prior year.
Cash flow from operations for the quarter was $94.0 million compared to net income in the
current quarter of $86.1 million. During the quarter we paid $49.7
million in dividends and repaid $60.0 million of our outstanding debt.
Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.35 per share. The
dividend will have a record date of November 9, 2017, payable on December
14, 2017. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock
Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount
in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE
shares. The ex-dividend date will be November 8, 2017 for common stock holders and for CDI holders.
ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions
between its common stock and CDI registers from November 8, 2017 through November 9, 2017 inclusive.
Webcast details
ResMed will discuss its first quarter fiscal year 2018 results on its webcast at 1:30 p.m. U.S.
Pacific Time today. The live webcast of the call can be accessed on ResMed's Investor Relations website at investor.resmed.com. Please go to this
section of the website and click on the icon for the "Q1 2018 earnings webcast" to register and listen to the live webcast. A
replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast.
In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by
dialing 800-585-8367 (U.S.) and +1 416-621-4642 (outside U.S.) and entering a passcode of 93203758. The telephone replay will be
available until November 9, 2017.
About ResMed
ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more than 4 million patients remotely monitored every day. Our
6,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.
Safe harbor statement
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the
Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed's
projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its
products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to
materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are
discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not
undertake to update its forward-looking statements.
|
RESMED INC AND SUBSIDIARIES
|
|
Condensed Consolidated Statements of Income (Unaudited)
|
|
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
|
Net revenue
|
$
|
523,659
|
|
$
|
465,450
|
|
|
Cost of sales
|
|
218,054
|
|
|
191,196
|
|
|
Astral field safety notification expenses (1)
|
|
-
|
|
|
5,070
|
|
|
Gross profit
|
|
305,605
|
|
|
269,184
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
143,849
|
|
|
128,851
|
|
|
Research and development
|
|
37,415
|
|
|
34,446
|
|
|
Amortization of acquired intangible assets (1)
|
|
11,783
|
|
|
11,741
|
|
|
Total operating expenses
|
|
193,047
|
|
|
175,038
|
|
|
Income from operations (1)
|
|
112,558
|
|
|
94,146
|
|
|
|
|
|
|
|
|
|
Other income (expenses), net:
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
(2,915)
|
|
|
(2,493)
|
|
|
Other, net
|
|
(1,158)
|
|
|
1,272
|
|
|
Total other income (expenses), net
|
|
(4,073)
|
|
|
(1,221)
|
|
|
Income before income taxes
|
|
108,485
|
|
|
92,925
|
|
|
Income taxes
|
|
22,360
|
|
|
16,818
|
|
|
Net income (1)
|
$
|
86,125
|
|
$
|
76,107
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
$
|
0.61
|
|
$
|
0.54
|
|
|
Diluted earnings per share
|
$
|
0.60
|
|
$
|
0.54
|
|
|
Non-GAAP diluted earnings per share (1)
|
$
|
0.66
|
|
$
|
0.62
|
|
|
|
|
|
|
|
|
|
Basic shares outstanding
|
|
142,247
|
|
|
140,785
|
|
|
Diluted shares outstanding
|
|
143,480
|
|
|
142,090
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
See the reconciliation of non-GAAP financial measures in the table at
the end of the press release.
|
|
RESMED INC AND SUBSIDIARIES
|
|
Condensed Consolidated Balance Sheets (Unaudited - In thousands)
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
June 30,
|
|
|
|
2017
|
|
|
2017
|
|
|
ASSETS
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
811,102
|
|
$
|
821,935
|
|
|
Accounts receivable, net
|
|
431,354
|
|
|
450,530
|
|
|
Inventories
|
|
300,472
|
|
|
268,319
|
|
|
Prepayments and other current assets
|
|
115,018
|
|
|
103,219
|
|
|
Total current assets
|
|
1,657,946
|
|
|
1,644,003
|
|
|
Property, plant and equipment, net
|
|
400,795
|
|
|
394,241
|
|
|
Goodwill
|
|
1,072,298
|
|
|
1,064,874
|
|
|
Other intangibles, net
|
|
251,025
|
|
|
261,800
|
|
|
Deferred income taxes and other non-current assets
|
|
107,553
|
|
|
103,569
|
|
|
Total non-current assets
|
|
1,831,671
|
|
|
1,824,484
|
|
|
Total assets
|
$
|
3,489,617
|
|
$
|
3,468,487
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
Accounts payable
|
|
85,082
|
|
|
92,763
|
|
|
Accrued expenses
|
|
179,228
|
|
|
186,295
|
|
|
Deferred revenue
|
|
53,294
|
|
|
51,918
|
|
|
Income taxes payable
|
|
33,981
|
|
|
29,150
|
|
|
Total current liabilities
|
|
351,585
|
|
|
360,126
|
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
Deferred revenue
|
|
55,692
|
|
|
53,235
|
|
|
Deferred income taxes
|
|
11,566
|
|
|
13,822
|
|
|
Other long term liabilities
|
|
2,375
|
|
|
2,427
|
|
|
Long-term debt
|
|
1,018,871
|
|
|
1,078,611
|
|
|
Total non-current liabilities
|
|
1,088,504
|
|
|
1,148,095
|
|
|
Total liabilities
|
|
1,440,089
|
|
|
1,508,221
|
|
|
STOCKHOLDERS' EQUITY:
|
|
|
|
|
|
|
|
Common stock
|
|
569
|
|
|
569
|
|
|
Additional paid-in capital
|
|
1,395,576
|
|
|
1,379,130
|
|
|
Retained earnings
|
|
2,352,664
|
|
|
2,316,237
|
|
|
Treasury stock
|
|
(1,546,611)
|
|
|
(1,546,611)
|
|
|
Accumulated other comprehensive income
|
|
(152,670)
|
|
|
(189,059)
|
|
|
Total stockholders' equity
|
$
|
2,049,528
|
|
$
|
1,960,266
|
|
|
Total liabilities and stockholders' equity
|
$
|
3,489,617
|
|
$
|
3,468,487
|
|
|
RESMED INC AND SUBSIDIARIES
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited - In
thousands)
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
Net income
|
$
|
86,125
|
|
$
|
76,107
|
|
|
Adjustment to reconcile net income to cash provided by operating
activities:
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
29,571
|
|
|
27,775
|
|
|
Stock-based compensation costs
|
|
11,948
|
|
|
12,049
|
|
|
Impairment of cost-method investments
|
|
962
|
|
|
-
|
|
|
Changes in operating assets and liabilities, net of effect of
acquisitions:
|
|
|
|
|
|
|
|
Accounts receivable, net
|
|
23,317
|
|
|
36,207
|
|
|
Inventories, net
|
|
(26,942)
|
|
|
(28,073)
|
|
|
Prepaid expenses, net deferred income taxes and other current
assets
|
|
(15,408)
|
|
|
(19,115)
|
|
|
Accounts payable, accrued expenses and other
|
|
(15,590)
|
|
|
(18,707)
|
|
|
Net cash provided by operating activities
|
|
93,983
|
|
|
86,243
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
Purchases of property, plant and equipment
|
|
(16,030)
|
|
|
(14,560)
|
|
|
Patent registration costs
|
|
(2,242)
|
|
|
(2,471)
|
|
|
Business acquisitions, net of cash acquired
|
|
-
|
|
|
(3,090)
|
|
|
Investments in cost-method investments
|
|
(3,225)
|
|
|
(2,758)
|
|
|
Proceeds / (Payments) on maturity of foreign currency contracts
|
|
6,073
|
|
|
9,710
|
|
|
Net cash used in investing activities
|
|
(15,424)
|
|
|
(13,169)
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net
|
|
3,615
|
|
|
6,330
|
|
|
Proceeds from borrowings, net of borrowing costs
|
|
50,000
|
|
|
25,000
|
|
|
Repayment of borrowings
|
|
(110,000)
|
|
|
(25,000)
|
|
|
Dividends paid
|
|
(49,698)
|
|
|
(46,378)
|
|
|
Net cash (used in) / provided by financing activities
|
|
(106,083)
|
|
|
(40,048)
|
|
|
Effect of exchange rate changes on cash
|
|
16,691
|
|
|
17,198
|
|
|
Net increase / (decrease) in cash and cash equivalents
|
|
(10,833)
|
|
|
50,224
|
|
|
Cash and cash equivalents at beginning of period
|
|
821,935
|
|
|
731,434
|
|
|
Cash and cash equivalents at end of period
|
$
|
811,102
|
|
$
|
781,658
|
|
|
Reconciliation of Non-GAAP Financial Measures (Unaudited)
|
|
(In US$ thousands, except share and per share data)
|
|
|
The measure, "non-GAAP income from operations" is reconciled with GAAP
income from operations below:
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
GAAP income from operations
|
$
|
112,558
|
|
$
|
94,146
|
|
|
Astral battery field safety notification expenses
(A)
|
|
-
|
|
|
5,070
|
|
|
Amortization of acquired intangible assets (A)
|
|
11,783
|
|
|
11,741
|
|
|
Non-GAAP income from operations
|
$
|
124,341
|
|
$
|
110,957
|
|
|
|
|
|
|
|
|
|
The measures "non-GAAP net income" and "non-GAAP diluted earnings per
share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
|
|
|
Three Months Ended
|
|
|
|
September 30,
|
|
|
|
2017
|
|
|
2016
|
|
|
GAAP net income
|
$
|
86,125
|
|
$
|
76,107
|
|
|
Astral battery field safety notification expenses
(A)
|
|
-
|
|
|
3,549
|
|
|
Amortization of acquired intangible assets, net of tax
(A)
|
|
8,013
|
|
|
8,006
|
|
|
Non-GAAP net income (A)
|
$
|
94,138
|
|
$
|
87,662
|
|
|
Diluted shares outstanding
|
|
143,480
|
|
|
142,090
|
|
|
GAAP diluted earnings per share
|
$
|
0.60
|
|
$
|
0.54
|
|
|
Non-GAAP diluted earnings per share (A)
|
$
|
0.66
|
|
$
|
0.62
|
|
|
|
|
(A)
|
ResMed adjusts for the impact of the amortization of acquired intangible
assets and Astral battery field safety notification expenses from their evaluation of ongoing operations and believes
investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating
performance.
|
|
|
|
ResMed believes that non-GAAP diluted earnings per share is an additional
measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP
information internally in planning, forecasting, and evaluating the results of operations in the current period and in
comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed's
performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to
supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures,
non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included
under GAAP.
|
View original content with multimedia:http://www.prnewswire.com/news-releases/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2018-300544301.html
SOURCE ResMed Inc.